Biochemical Journal
August 1, 1954
Joyce L. Lewis, H. Mcilwain
29 citations
Research Article| August 01 1954 The action of some ergot derivatives, mescaline and dibenamine on the metabolism of separated mammalian cerebral tissues Joyce L. Lewis; Joyce L. Lewis 1Department of Biochemistry, Institute of Psychiatry (British Postgraduate Medical Federation, University of London), Maudsley Hospital, S.E. 5 Search for other works by this author on: This Site PubMed Google...
American Journal of Psychiatry
March 1, 1950
Thomas Thale, Beverly W. Gabrio, Kurt Salomon
5 citations
Mescaline produces altered visual experiences of several types, whose vividness and degree of distortion is proportionate to the size of the dose. There are no sharp boundaries dividing abnormal sensibility, illusions, and hallucinations. Subjects who gave fewer responses of the type "I see it" when asked to imagine situations were more likely to hallucinate than other patients. Visual...
Harvard Review of Psychiatry
Jan Dirk Blom, Rosemarij J. B. van Veen, Emma H. C. van Rooijen et al.
Sexual hallucinations are little known, yet often extremely burdening, phenomena. In this systematic review, we summarize what is known about their phenomenology, prevalence, etiopathology, ensuing distress, and treatment options. Sexual hallucinations can be experienced as genital or orgasmic sensations, although other sensory modalities can also be involved. With the notable exception of...
Journal of Addiction Medicine
Dafna Sara Rubin-Kahana, Ahmed Nabeel Hassan, Bernard Le Foll
In the last 2 decades, there is a renaissance in the scientific investigation of the therapeutic potential of psychedelic compounds. It is studied for the treatment of many psychiatric disorders, including posttraumatic stress disorder. The treatment is always done in the setting of psychedelic-assisted psychotherapy. A little is known about the potential effects, outside of the setting of...
American Journal of Therapeutics
Burton J. Tabaac, Kenneth Shinozuka, Mahdi Fadel et al.
Mescaline (3,4,5-trimethoxyphenethylamine) is a classic serotonergic psychedelic with a history of indigenous ceremonial use. There is renewed scientific interest in mescaline because of the potential psychiatric benefits of psychedelic-assisted therapy. Mescaline primarily exerts its psychoactive effects through serotonin-2A (5-HT 2A ) receptor agonism. There is a lack of controlled clinical...
Journal of Clinical Psychopharmacology
John L. Havlik, Sayana Isaac, Pralahad Raman et al.
With a rapid rise in clinical trials investigating psychogenic substances, the field faces considerable concerns regarding transparency and conflicts of interest. This study aims to systematically characterize ongoing NIH-registered clinical trials investigating psychogenic substances for psychiatric disorders as of late 2024, including research protocols, institutional settings, and funding...
Journal of Addiction Medicine
Babak Tofighi, Christina Marini, Joshua D Lee et al.
1 citation
Recent findings support the provision of meditation-based interventions (MBIs) in primary care. However, the acceptability of MBI among patients prescribed medications for opioid use disorder (eg, buprenorphine) in primary care remains unclear. This study assessed experiences and preferences for adopting MBI among patients prescribed buprenorphine in office-based opioid treatment (OBOT). This...
Journal of Addiction Medicine
Kevin H. Yang, Wayne Kepner, Anamika Nijum et al.
11 citations
3,4-Methylenedioxymethamphetamine (MDMA) (also known as "ecstasy" or "Molly") has regained attention in recent years for its efficacy in treating posttraumatic stress disorder, and the drug was granted breakthrough therapy designation for such use by the US Food and Drug Administration in 2017. However, little is known about the current epidemiology of recreational ecstasy/MDMA use. We...
American Journal of Therapeutics
Kenneth Shinozuka, Burton J. Tabaac, Alejandro Arenas et al.
After becoming notorious for its use as a party drug in the 1980s, 3,4-methylenedioxy-methampetamine (MDMA), also known by its street names "molly" and "ecstasy," has emerged as a powerful treatment for post-traumatic stress disorder (PTSD). There are extensive data about the risk profile of MDMA. However, the literature is significantly biased. Animal models demonstrating neurotoxic or adverse...
American Journal of Therapeutics
Viviana D. Evans, Alejandro Arenas, Kenneth Shinozuka et al.
10 citations
Ketamine, an arylcyclohexylamine dissociative anesthetic agent, has evolved into a versatile therapeutic. It has a rapid-onset, well-understood cardiovascular effects and a favorable safety profile in clinical use. Its enantiomeric compound, esketamine, was approved by the Food and Drug Administration in 2019 for both treatment-resistant depression and major depressive disorder with suicidal...